Teva Pharmaceutical Industries Limited (TEVA) Announces Court Adopts All Relevant Teva Claim Construction Interpretations in Copaxone® Patent Infringement Case Against Sandoz, Inc./Momenta Pharmaceuticals, Inc. (MNTA) and Mylan Pharmaceuticals, Inc. (MYL)/Natco Pharma Limited; Court Denies Mylan’s Summary Judgment Motion of Invalidity  
8/29/2011 10:16:18 AM

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that the U.S. District Court for the Southern District of New York has issued a favorable set of claim construction rulings in the Company’s patent infringement lawsuit against Sandoz Inc./Momenta Pharmaceuticals, Inc. and Mylan/Natco regarding Teva’s multiple sclerosis (MS) product, Copaxone®. The Court adopted all relevant Teva claim construction interpretations and rejected all of the claim construction interpretations put forth by Sandoz/Momenta and Mylan/Natco. In addition, the Court denied Mylan’s motion for summary judgment that the patents at issue are invalid for indefiniteness.